Countries going to India will receive doses in proportion to the size of the population.
The COVAX Initiative for Equal Global Access to COVID-19 Vaccines has published its first distribution list, planning adequate doses for dozens of countries that would have vaccinated more than 3 percent of their population by mid-year is.
The release of an “interim distribution forecast” on Wednesday raised concerns over whether low-income countries would be excluded from the vaccination race dominated by wealthy countries – a problem COVAX, led by the UN-backed vaccine alliance Mavi Has been established to address the Alliance for the Preparation of Epidemics (CEPI) and the World Health Organization (WHO).
In line with a goal to “protect the most vulnerable groups such as health care workers” in the first half of the year, the program’s first 337.2 million doses would be distributed, breaking the list for the first time.
The first delivery is expected at the end of February, with some 145 countries aiming to get enough doses to vaccinate 3.3 percent of the population by mid-2021.
.@CEPvaccines, @Vagavi And as co-lead of WHO, #COVAX Initiatives for equitable access #COVID-19 Vaccines, with key delivery partners @UNICEF, Are pleased to publish 1 interim distribution forecast of COVAX: https://t.co/RybRS5Fbuy #VaccinEquitypic.twitter.com/lrk6SNWnkq
– World Health Organization (WHO) (@WHO) 3 February, 2021
India (97.2 million), Pakistan (17.2 million), Nigeria (16 million), Indonesia (13.7 million), Bangladesh (12.8 million) and Brazil (10.6 million) will receive doses in proportion to population size with the highest population. .
Rich self-financing countries were on the list, in addition to low-income countries including South Korea (2.6 million doses), Canada (1.9 million) and New Zealand (250,000).
The distribution list includes 240 million doses of the AstraZeneca-Oxford vaccine, which has been licensed to the Serum Institute of India (SII); 96 million doses of the AstraZeneca-Oxford vaccine; And 1.2 million doses of the Pfizer-BioNtech vaccine.
The Pfizer-BioNTech vaccine is the only one to receive emergency use approval from the World Health Organization (WHO). Evaluation is underway for the AstraZeneca-Oxford vaccine. Both require two injection doses.
A statement emphasized that the list is non-binding and may change, but will allow countries to plan how many doses they will receive in the first round.
“It’s fantastic. We can start the vaccination. It’s coming up next week,” WHO’s coordinator of the vaccination program Ann Lindstrand said at a news conference.
The program’s co-leader, Frederick Christenson, deputy CEO for the Alliance for Epidemiologic Preparedness Innovation (CEPI), said the plan came at a “critical moment” in the fight against the coronovirus of the new variants and a lopped vaccine roll-out so far – In favor of rich countries.
“We are indeed on a path to start balancing a global map that has so far shown how many low-income countries have not yet started vaccinating a person, while other, wealthier countries are largely Proceed towards vaccination, ”he said.
In the long run, COVAX aims to secure enough vaccines for at least the most vulnerable 20 percent of participating countries by the end of 2021.
Its funding is covered through donations for 92 lower and lower-middle-income economies, while for wealthy countries, it serves as a back-up insurance policy for their own immunization programs.
But the system has faced challenges as rich countries have decreased their supply of vaccines, sometimes at premium prices, and reduce the goal of vaccine delivery similar to the WHO.
Program leaders have faced issues of striking deals with drug manufacturers, and only a handful of the two billion doses secured for COVAX have been received by the firms.